WO2023209692 - INHIBITORS OF ROCK2
National phase entry:
Publication Number
WO/2023/209692
Publication Date
02.11.2023
International Application No.
PCT/IB2023/054494
International Filing Date
29.04.2023
Title **
[English]
INHIBITORS OF ROCK2
[French]
INHIBITEURS DE ROCK2
Applicants **
GRAVITON BIOSCIENCE BV
Inventors
WAKSAL, Samuel D.
ZANIN-ZHOROV, Alexandra
KACHKOVSKYI, Georgiy
SOLUCH, Magdalena
JĘDRZEJCZAK, Anna
KLVAŇA, Martin
DOMAGAŁA, Dominik
Priority Data
63/336,667
29.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2619 | |
| EPO | Filing, Examination, Granting | 13980 | |
| Japan | Filing, Examination, Granting | 2502 | |
| South Korea | Filing, Examination, Granting | 2754 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
27,195
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to inhibitors of Rho-associated protein kinase (ROCK), pharmaceutical compositions comprising the same, and use thereof for the prevention or treatment of a disease mediated by the ROCK. Particularly, the inhibitors of ROCK are selective for the inhibition of ROCK2.[French]
La présente divulgation concerne des inhibiteurs de la protéine kinase associée à Rho (ROCK), des compositions pharmaceutiques les comprenant, et leur utilisation pour la prévention ou le traitement d'une maladie médiée par la ROCK. En particulier, les inhibiteurs de ROCK sont sélectifs pour l'inhibition de ROCK2.